Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Early research (Phase 1)Study completedNCT03329950
What this trial is testing

CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Who this might be right for
MelanomaNon-small Cell Lung CancerBreast Cancer+23 more
Celldex Therapeutics 132
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Large-scale testing (Phase 3)Study completedNCT04294810
What this trial is testing

Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 620
Early research (Phase 1)Study completedNCT03761017
What this trial is testing

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Who this might be right for
Squamous Cell Non Small Cell Lung CancerProstate Cancer MetastaticCutaneous Melanoma+3 more
MacroGenics 162
Testing effectiveness (Phase 2)Ended earlyNCT00334763
What this trial is testing

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Northwestern University 32
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Early research (Phase 1)Study completedNCT02892123
What this trial is testing

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Who this might be right for
HER2-expressing Cancers
Jazz Pharmaceuticals 279
Testing effectiveness (Phase 2)Active Not RecruitingNCT06003231
What this trial is testing

Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Who this might be right for
Carcinoma, Non-Small-Cell LungOvarian NeoplasmsEndometrial Neoplasms+1 more
Seagen, a wholly owned subsidiary of Pfizer 120
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH 270
Early research (Phase 1)Active Not RecruitingNCT04676477
What this trial is testing

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 246
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Study completedNCT03625323
What this trial is testing

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Who this might be right for
NSCLCHNSCC
Immutep S.A.S. 187
Testing effectiveness (Phase 2)Study completedNCT00356122
What this trial is testing

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Sanofi 53
Testing effectiveness (Phase 2)Looking for participantsNCT06632262
What this trial is testing

Clinical Study of ABSK061 and ABSK043

Who this might be right for
HER2-Gastric/Gastroesophageal Junction CancerUrothelial CarcinomaNon-Small Cell Lung Cancer+1 more
Abbisko Therapeutics Co, Ltd 202
Early research (Phase 1)Looking for participantsNCT07589205
What this trial is testing

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Who this might be right for
Solid TumorColorectal CancerNon-small Cell Lung Cancer+2 more
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 493
Testing effectiveness (Phase 2)WithdrawnNCT05180422
What this trial is testing

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Who this might be right for
Non Small Cell Lung Cancer
Criterium, Inc.
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85